← All themes

Immunotherapy & Oncology

Cancer treatment has moved from poisoning dividing cells towards directing the immune system at the tumour, and towards drugs that carry their payload only to cancerous tissue. It absorbs more drug development spending than any other area.

388 stocks

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Johnson & Johnson JNJ $617B	2,195	+99	+5%	$188B
2	2 Pfizer PFE $169B	1,970	+90	+5%	$146B
3	3 Merck MRK $368B	1,755	+82	+5%	$109B
4	4 AbbVie ABBV $508B	1,637	+32	+2%	$65.8B
5	5 Gilead Sciences GILD $197B	1,630	+55	+3%	$115B
6	6 Bristol-Myers Squibb BMY $125B	1,535	+81	+6%	$84.9B
7	7 Amgen AMGN $238B	1,455	+73	+5%	$98.6B
8	8 Novartis NVS $287B	927	+1	+0.1%	$20.2B
9	9 GSK GSK $98.7B	719	+12	+2%	$8.7B
10	10 Regeneron Pharmaceuticals REGN $82.9B	577	+14	+2%	$39.7B
11	11 AstraZeneca AZN $260B	390	+19	+5%	$7.54B
12	12 Incyte INCY $23.1B	381	+17	+5%	$18.9B
13	13 Jazz Pharmaceuticals JAZZ $14B	346	-16	-4%	$7.92B
14	14 Opko Health OPK $1.19B	273	+5	+2%	$1.16B
15	15 Myriad Genetics MYGN $419M	233	-2	-0.9%	$3.88B
16	SGEN 16 DELISTED Seagen Inc. Common Stock SGEN	231	+7	+3%	$6.33B
17	17 DELISTED Assertio ASRT	206	-2	-1%	$1.12B
18	18 DELISTED Exact Sciences EXAS	183	-9	-5%	$852M
19	19 Precigen PGEN $2.64B	180	+7	+4%	$3.09B
20	20 Halozyme HALO $13.7B	166	-9	-5%	$1.71B
21	CLVS 21 DELISTED Clovis Oncology, Inc. CLVS	157	-35	-18%	$1.39B
22	22 DELISTED Immunogen Inc IMGN	152	+1	+0.7%	$1.05B
23	23 DELISTED Lumos Pharma, Inc. Common Stock LUMO	152	0	0%	$590M
24	24 DELISTED Radius Health, Inc. RDUS	148	+21	+17%	$2.3B
25	25 Exelixis EXEL $15.6B	146	+10	+7%	$984M